These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 15637688)
1. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Dunnwald LK; Gralow JR; Ellis GK; Livingston RB; Linden HM; Lawton TJ; Barlow WE; Schubert EK; Mankoff DA Cancer; 2005 Feb; 103(4):680-8. PubMed ID: 15637688 [TBL] [Abstract][Full Text] [Related]
2. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Drucker MJ; Livingston RB Cancer; 1999 Jun; 85(11):2410-23. PubMed ID: 10357412 [TBL] [Abstract][Full Text] [Related]
3. Dual phase qualitative and quantitative 99mTc-MIBI scintimammography for predicting response to neoadjuvant chemotherapy in breast cancer. Zaman MU; Nasir Z; Raza T; Hashmi H; Hashmi A; Fatima N J Coll Physicians Surg Pak; 2009 Mar; 19(3):173-8. PubMed ID: 19268018 [TBL] [Abstract][Full Text] [Related]
4. In Vivo Detection of Multidrug-Resistance Related Proteins in Locally Advanced Breast Cancer Using 99mTc-MIBI SPECT/CT Imaging: Correlation with Clinical Outcomes. Mostafa NM; Elnaggar MS; Abdelhafez YG; Rezk K; Sherif MF; Eltyb HA; Ahmed S; Abu Elnga NE; Hussien MT Asian Pac J Cancer Prev; 2024 Sep; 25(9):3125-3141. PubMed ID: 39342592 [TBL] [Abstract][Full Text] [Related]
5. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. Ciarmiello A; Del Vecchio S; Silvestro P; Potena MI; Carriero MV; Thomas R; Botti G; D'Aiuto G; Salvatore M J Clin Oncol; 1998 May; 16(5):1677-83. PubMed ID: 9586878 [TBL] [Abstract][Full Text] [Related]
6. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. Maini CL; Tofani A; Sciuto R; Semprebene A; Cavaliere R; Mottolese M; Benevolo M; Ferranti F; Grandinetti ML; Vici P; Lopez M; Botti C J Nucl Med; 1997 Oct; 38(10):1546-51. PubMed ID: 9379190 [TBL] [Abstract][Full Text] [Related]
7. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899 [TBL] [Abstract][Full Text] [Related]
8. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography. Mezi S; Primi F; Capoccetti F; Scopinaro F; Modesti M; Schillaci O Int J Oncol; 2003 Jun; 22(6):1233-40. PubMed ID: 12738988 [TBL] [Abstract][Full Text] [Related]
9. Dynamic imaging: scintimammography. Salvatore M; Del Vecchio S Eur J Radiol; 1998 May; 27 Suppl 2():S259-64. PubMed ID: 9652532 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. Sciuto R; Pasqualoni R; Bergomi S; Petrilli G; Vici P; Belli F; Botti C; Mottolese M; Maini CL J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317 [TBL] [Abstract][Full Text] [Related]
11. Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99m)Tc-Sestamibi uptake. Marshall C; Eremin J; El-Sheemy M; Eremin O; Griffiths PA Nucl Med Commun; 2005 Jan; 26(1):9-15. PubMed ID: 15604942 [TBL] [Abstract][Full Text] [Related]
12. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT. Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326 [TBL] [Abstract][Full Text] [Related]
13. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy. Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695 [TBL] [Abstract][Full Text] [Related]
14. Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography. Tiling R; Kessler M; Untch M; Sommer H; Linke R; Brinkbäumer K; Hahn K Onkologie; 2003 Feb; 26(1):27-31. PubMed ID: 12624514 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. Travaini LL; Baio SM; Cremonesi M; De Cicco C; Ferrari M; Trifirò G; Prisco G; Viale G; Colleoni MA; Radice D; Sivolapenko GB; Paganelli G Breast; 2007 Jun; 16(3):262-70. PubMed ID: 17291755 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy. Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887 [TBL] [Abstract][Full Text] [Related]
18. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients. Sergieva SB; Timcheva KV; Hadjiolov ND J BUON; 2006; 11(1):61-8. PubMed ID: 17318954 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997 [TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Tiling R; Linke R; Untch M; Richter A; Fieber S; Brinkbäumer K; Tatsch K; Hahn K Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]